85%Confidence
0Views
FDASource
2026-04-20Date
Summary
Fresenius Kabi's sterility recall extends to a larger volume saline product, suggesting widespread contamination risks. This may necessitate a comprehensive manufacturing overhaul and increased capital expenditures.
Actionable: Consider reducing exposure to Fresenius Kabi until the scope of the manufacturing issues is fully understood.
AI Confidence: 85%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL) 500 mL in a Single Dose freeflex bag, 500 mL x 20, Manufactured for: Fresenius Kab
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now